Nasdaq
$19.88▲ 1.56%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $954.9MShares out 48.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
2- 5d agoPre-market26.10.20 20:008-KKey event#●●●#●●●#●●●
Odyssey Therapeutics, Inc.Bullish
Odyssey Therapeutics announced results from the completed Phase 2a induction period for its ulcerative colitis candidate, OD-001. The 20 mg twice-daily cohort met the primary endpoint of change in modified Mayo score with a 27% clinical remission rate, and the company plans to advance into Phase 2b monotherapy and Phase 2a combination trials.…more
$19.88+1.56%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.4Pre-market26.08.04 20:008-KKey event
Odyssey Therapeutics, Inc.
오디세이 테라퓨틱스는 2026년 2분기 실적 발표를 통해 5,280만 달러의 순손실을 기록했으며, 6월 30일 기준 4억 3,310만 달러의 현금성 자산을 보유하여 2028년 하반기까지 운영 자금을 확보했습니다. 주요 파이프라인인 OD-001의 임상 2a상 데이터는 10월 유럽 소화기학회에서 발표될 예정이며, 하반기 중 OD-001의 임상 2b상 및 병용 임상 2a상 개시와 OD-002의 임상시험계획(CTA) 제출을 계획하고 있습니다.…more
$19.88+1.56%vs prev closeView filingShare
1 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 20:00#●●●#●●●#●●●
Odyssey Therapeutics Reports Positive Phase 2a Results for OD-001 in Ulcerative Colitis…more
Odyssey Therapeutics announced positive Phase 2a induction results for its oral ulcerative colitis treatment, OD-001, demonstrating clinical efficacy and safety. The company plans to advance into Phase 2b and combination trials, though the current data stems from an open-label study without a concurrent placebo control.…more
$19.88+1.56%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.12Pre-market26.10.12 21:03
●●●●●●●● ●●●●● ●●●●●●
Odyssey Therapeutics will present the design of a Phase 2a trial evaluating the combination of OD-001 and vedolizumab for ulcerative colitis at the ACG 2026 meeting. The study aims to test a dual-targeting strategy for immune inflammation, with topline results expected in the second half of 2027.…more
$19.88+1.56%vs prev closeShareBenzinga - 10.6Pre-market26.10.06 21:07
●●●●●●●● ●●●●● ●●●●●●
Odyssey Therapeutics will present additional Phase 2a data for its ulcerative colitis candidate, OD-001, at the UEG Week on October 20. The presentation provides an update on the drug's clinical progress, with future value dependent on subsequent trial results.…more
$19.88+1.56%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report